ARTICLE | Finance
CAR T confidence
How China’s JW leveraged growing enthusiasm for CAR T to raise $90M series A
March 9, 2018 12:07 AM UTC
The first CAR T therapy approvals in the U.S. followed by CFDA guidelines on cell therapy development and manufacturing gave a boost to Chinese investor interest in the space, enabling JW Therapeutics (Shanghai) Co. Ltd. to raise a $90 million series A round.
Temasek, Sequoia Capital China and YuanMing Capital led the round, which closed on March 7. Fellow new investors Oriza Seed Capital, Yipu Capital, AVICT Global Holdings, Shiyu Capital and LVC Capital Fund also participated, as did existing investors WuXi AppTec Co. Ltd. and Juno Therapeutics Inc., which Celgene Corp. (NASDAQ:CELG) acquired...